Document Detail


Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.
MedLine Citation:
PMID:  23622132     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Immune cells are important in the pathogenesis of acute pancreatitis and determine disease severity. Results from cytokine-based clinical trials for acute pancreatitis have been disappointing, so strategies that target and alter the behavior of infiltrating immune cells require consideration. Recurrent acute pancreatitis can progress to chronic pancreatitis, which is a well-described risk factor for pancreatic ductal adenocarcinoma (PDA). However, most patients with chronic pancreatitis do not develop PDA, and most patients with PDA do not have a history of pancreatitis. Interestingly, chronic pancreatitis and PDA tissues have similarities in their desmoplasia and inflammatory infiltrates, indicating overlapping inflammatory responses. Further studies are needed to determine the differences and similarities of these responses, improve our understanding of PDA pathogenesis, and develop specific immune-based therapies. Immune cells in PDA produce immunosuppressive signals that allow tumors to evade the immune response. Unlike single therapeutic agent studies that block immunosuppressive mechanisms, studies of combination therapies that include therapeutic vaccines have provided promising results.
Authors:
Lei Zheng; Jing Xue; Elizabeth M Jaffee; Aida Habtezion
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Gastroenterology     Volume:  144     ISSN:  1528-0012     ISO Abbreviation:  Gastroenterology     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-04-29     Completed Date:  2013-06-20     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  0374630     Medline TA:  Gastroenterology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1230-40     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adaptive Immunity
Animals
Carcinoma, Pancreatic Ductal / immunology,  pathology,  therapy*
Disease Progression
Humans
Immunity, Innate
Immunotherapy* / methods
Pancreas / immunology*,  pathology
Pancreatic Neoplasms / immunology,  pathology,  therapy*
Pancreatitis / immunology,  pathology,  therapy*
Pancreatitis, Chronic / immunology,  pathology,  therapy
Risk Factors
Treatment Outcome
Grant Support
ID/Acronym/Agency:
DK56339/DK/NIDDK NIH HHS; K23 CA148964/CA/NCI NIH HHS; K23 CA148964-01/CA/NCI NIH HHS; P50 CA062924-14/CA/NCI NIH HHS; R01 DK092421/DK/NIDDK NIH HHS; R01 DK092421/DK/NIDDK NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Roles for KRAS in pancreatic tumor development and progression.
Next Document:  Biology and clinical applications of pancreatic cancer stem cells.